JPH09504169A - Cd40に対する抗体 - Google Patents
Cd40に対する抗体Info
- Publication number
- JPH09504169A JPH09504169A JP7510807A JP51080795A JPH09504169A JP H09504169 A JPH09504169 A JP H09504169A JP 7510807 A JP7510807 A JP 7510807A JP 51080795 A JP51080795 A JP 51080795A JP H09504169 A JPH09504169 A JP H09504169A
- Authority
- JP
- Japan
- Prior art keywords
- binding
- antibody
- monoclonal antibody
- cells
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.CD40リガンド発現細胞への溶解性CD40の結合の少なくとも約9 0%阻害の観察によって判定されるような、ヒトCD40分子に特異的に結合し 、CD40分子のCD40リガンドへの結合を阻害するモノクローナル抗体。 2.ネズミモノクローナル抗体とヒトモノクローナル抗体とから成る群から 選択される請求項1記載のモノクローナル抗体。 3.HuCD40−M2(ATCC HB 11459)と、CD40リガ ンド発現細胞への溶解性CD40の結合の少なくとも約90%阻害の観察によっ て判定されるような、HuCD40−M2のCD40リガンド阻害特性を有する モノクローナル抗体とから成る群から選択される請求項2記載のネズミモノクロ ーナル抗体。 4.抗体がネズミハイブリドーマHuCD40−M2(ATCC HB 1 1459)によって産生される請求項3記載のネズミモノクローナル抗体。 5.請求項1〜4のいずれかに記載の抗体又はCD40に特異的に結合する その部分をコードするDNA配列によってコードされるCD40結合ドメインを 含む、CD40に特異的に結合する結合タンパク質。 6.ヒト化モノクローナル抗体と、一本鎖Fvフラグメントと、二価Fvフ ラグメントとから成る群から選択される請求項5記載の結合タンパク質。 7.請求項1〜4のいずれかに記載のCD40に対するモノクローナル抗体 と、生理学的に許容されるキャリヤー又は希釈剤とを含む治療用組成物。 8.請求項5又は6のいずれかに記載のCD40に対するモノクローナル抗 体と、生理学的に許容されるキャリヤー又は希釈剤とを含む治療用組成物。 9.CD40リガンド仲介免疫反応又は炎症反応の抑制方法であって、請求 項7又は8のいずれかに記載の治療用組成物の有効量を投与することを含む前記 方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13054193A | 1993-10-01 | 1993-10-01 | |
US08/130,541 | 1993-10-01 | ||
PCT/US1994/009984 WO1995009653A1 (en) | 1993-10-01 | 1994-09-02 | Antibodies to cd40 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09504169A true JPH09504169A (ja) | 1997-04-28 |
JP3675819B2 JP3675819B2 (ja) | 2005-07-27 |
Family
ID=22445171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51080795A Expired - Fee Related JP3675819B2 (ja) | 1993-10-01 | 1994-09-02 | Cd40に対する抗体 |
Country Status (15)
Country | Link |
---|---|
US (1) | US5801227A (ja) |
EP (1) | EP0724456B1 (ja) |
JP (1) | JP3675819B2 (ja) |
KR (1) | KR960704576A (ja) |
AT (1) | ATE255906T1 (ja) |
AU (1) | AU686230B2 (ja) |
CA (1) | CA2172376C (ja) |
DE (1) | DE69433406T2 (ja) |
DK (1) | DK0724456T3 (ja) |
ES (1) | ES2211884T3 (ja) |
FI (1) | FI961285A (ja) |
NO (1) | NO961151D0 (ja) |
NZ (1) | NZ273504A (ja) |
PT (1) | PT724456E (ja) |
WO (1) | WO1995009653A1 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
CA2213798C (en) * | 1995-03-01 | 2001-02-06 | Immunex Corporation | Method for stimulating an immune response |
US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
US20020102706A1 (en) * | 1997-06-18 | 2002-08-01 | Genentech, Inc. | Apo-2DcR |
EP2083079A1 (en) * | 1997-06-18 | 2009-07-29 | Genentech, Inc. | Apo-2DcR |
CN1762492A (zh) * | 1998-05-23 | 2006-04-26 | 莱顿大学医学中心 | Cd40结合分子和ctl肽在用于治疗肿瘤的药物组合物中的用途 |
WO2000066155A1 (en) | 1999-04-30 | 2000-11-09 | La Jolla Institute For Allergy And Immunology | Methods for preventing reactivation of latent virus and controlling virus replication |
US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
WO2001024823A1 (en) * | 1999-10-04 | 2001-04-12 | Chiron Corporation | Cd40 antagonist for treating psoriasis |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
BR0108001A (pt) * | 2000-02-01 | 2004-01-06 | Tanox Inc | Moléculas ativadoras de apc com ligação para cd-40 |
JP2003531178A (ja) * | 2000-04-25 | 2003-10-21 | アイデック ファーマスーティカルズ コーポレイション | 中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与 |
US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
AU2001259215A1 (en) * | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
US7288252B2 (en) | 2000-10-02 | 2007-10-30 | Novartis Vaccines And Diagnostics, Inc. | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
CA2436180C (en) | 2001-01-31 | 2011-11-08 | Idec Pharmaceutical Corporation | Immunoregulatory antibodies and uses thereof |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20020159996A1 (en) * | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20070065436A1 (en) * | 2001-01-31 | 2007-03-22 | Biogen Idec Inc. | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
EP2011802A3 (en) * | 2001-04-27 | 2009-04-15 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
US20030091593A1 (en) * | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
SI1680141T1 (sl) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostic | Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen |
US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
EP1756162A1 (en) | 2004-03-23 | 2007-02-28 | Biogen Idec MA Inc. | Receptor coupling agents and therapeutic uses thereof |
US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
CN101325970B (zh) * | 2005-11-01 | 2013-08-14 | 诺华有限公司 | 抗cd40抗体的应用 |
CA2627891A1 (en) * | 2005-11-01 | 2007-05-10 | Novartis Ag | Uses of anti-cd40 antibodies |
JP5290152B2 (ja) | 2006-04-21 | 2013-09-18 | ノバルティス アーゲー | 拮抗剤抗cd40抗体薬学的組成物 |
CA2652599C (en) * | 2006-05-03 | 2019-09-24 | Ross Kedl | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
WO2012125569A2 (en) | 2011-03-11 | 2012-09-20 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
MX339239B (es) | 2011-04-29 | 2016-05-18 | Apexigen Inc | Anticuerpos anti-cd40 y metodos de uso. |
CN104918957B (zh) | 2012-10-30 | 2018-11-16 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
US10174121B2 (en) | 2015-05-29 | 2019-01-08 | Abbvie, Inc. | Anti-CD40 antibodies |
CN116063481A (zh) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | 人源化抗-cd40抗体及其用途 |
CN109069622A (zh) | 2015-09-30 | 2018-12-21 | 詹森生物科技公司 | 特异性结合人cd40的拮抗性抗体和使用方法 |
EP3426271A4 (en) | 2016-03-10 | 2019-10-16 | Cold Genesys, Inc. | METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY |
JP7038064B2 (ja) | 2016-04-18 | 2022-03-17 | セルデックス セラピューティクス インコーポレイテッド | ヒトcd40に結合するアゴニスト抗体およびその使用 |
JP7261379B2 (ja) | 2016-06-20 | 2023-04-20 | カイマブ・リミテッド | 抗pd-l1抗体 |
CN110546164B (zh) * | 2016-11-11 | 2023-10-20 | 锦湖Ht株式会社 | 特异性结合cd40的抗体及其用途 |
WO2023025248A1 (zh) | 2021-08-26 | 2023-03-02 | 映恩生物制药(苏州)有限公司 | 一种甾体化合物及其缀合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5247069A (en) * | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
-
1994
- 1994-09-02 AT AT94927340T patent/ATE255906T1/de not_active IP Right Cessation
- 1994-09-02 CA CA002172376A patent/CA2172376C/en not_active Expired - Fee Related
- 1994-09-02 JP JP51080795A patent/JP3675819B2/ja not_active Expired - Fee Related
- 1994-09-02 PT PT94927340T patent/PT724456E/pt unknown
- 1994-09-02 DE DE69433406T patent/DE69433406T2/de not_active Expired - Fee Related
- 1994-09-02 NZ NZ273504A patent/NZ273504A/en not_active IP Right Cessation
- 1994-09-02 AU AU76819/94A patent/AU686230B2/en not_active Ceased
- 1994-09-02 WO PCT/US1994/009984 patent/WO1995009653A1/en active IP Right Grant
- 1994-09-02 EP EP94927340A patent/EP0724456B1/en not_active Expired - Lifetime
- 1994-09-02 KR KR1019960701469A patent/KR960704576A/ko not_active Application Discontinuation
- 1994-09-02 ES ES94927340T patent/ES2211884T3/es not_active Expired - Lifetime
- 1994-09-02 DK DK94927340T patent/DK0724456T3/da active
-
1995
- 1995-09-08 US US08/526,014 patent/US5801227A/en not_active Expired - Lifetime
-
1996
- 1996-03-20 FI FI961285A patent/FI961285A/fi unknown
- 1996-03-21 NO NO961151A patent/NO961151D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0724456A1 (en) | 1996-08-07 |
FI961285A0 (fi) | 1996-03-20 |
KR960704576A (ko) | 1996-10-09 |
CA2172376C (en) | 2008-11-18 |
ATE255906T1 (de) | 2003-12-15 |
NZ273504A (en) | 1997-12-19 |
NO961151L (no) | 1996-03-21 |
EP0724456A4 (en) | 1997-07-02 |
AU686230B2 (en) | 1998-02-05 |
FI961285A (fi) | 1996-03-20 |
JP3675819B2 (ja) | 2005-07-27 |
US5801227A (en) | 1998-09-01 |
EP0724456B1 (en) | 2003-12-10 |
AU7681994A (en) | 1995-05-01 |
PT724456E (pt) | 2004-04-30 |
DE69433406D1 (de) | 2004-01-22 |
CA2172376A1 (en) | 1995-04-13 |
DE69433406T2 (de) | 2004-10-07 |
DK0724456T3 (da) | 2004-04-13 |
NO961151D0 (no) | 1996-03-21 |
WO1995009653A1 (en) | 1995-04-13 |
ES2211884T3 (es) | 2004-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09504169A (ja) | Cd40に対する抗体 | |
RU2765306C2 (ru) | Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение | |
RU2709742C2 (ru) | Гуманизированные антитела к ox40 и способы их применения | |
JP5665702B2 (ja) | Nk細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物 | |
US20240002515A1 (en) | Methods and antibodies for modulation of immunoresponse | |
US20020155109A1 (en) | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 | |
US20220235142A1 (en) | Anti-ceacam5 monoclonal antibody, preparation method thereof and use thereof | |
CN112574312B (zh) | 一组ox40单克隆抗体及其医药用途 | |
CN110003338A (zh) | 抗ox40抗体及其应用 | |
TW202144435A (zh) | 一種抗cd19抗體的抗體及其製備和應用 | |
US20220064254A1 (en) | Anti-hk2 chimeric antigen receptor (car) | |
JP6845237B2 (ja) | 抗−ヒトil−3抗体、il−3の高められた発現又はレベルに関連する疾患又は機能障害へのそれらの使用、及びヒトil−3の検出方法へのそれらの使用 | |
TWI844684B (zh) | 一種抗ceacam5的單殖株抗體及其製備方法和用途 | |
US20230094867A1 (en) | Anti-idiotypic antibodies against anti-cd79b antibodies | |
US20220064284A1 (en) | Anti-idiotypic antibodies against anti-gprc5d antibodies | |
CN115803346A (zh) | Pd-1抗原结合蛋白及其应用 | |
CN116867807A (zh) | Siglec-15结合蛋白的制备及其用途 | |
Ferrari | Characterisation of scFv A7 reactivity and development of a novel bispecific antibody for targeted therapies in Rheumatoid Arthritis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040803 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041102 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050427 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090513 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100513 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110513 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110513 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120513 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |